About: Enantiomers of Chloroquine and Hydroxychloroquine Exhibit Different Activities Against SARS-CoV-2 in vitro, Evidencing S-Hydroxychloroquine as a Potentially Superior Drug for COVID-19

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Enantiomers of Chloroquine and Hydroxychloroquine Exhibit Different Activities Against SARS-CoV-2 in vitro, Evidencing S-Hydroxychloroquine as a Potentially Superior Drug for COVID-19 Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Enantiomers of Chloroquine and Hydroxychloroquine Exhibit Different Activities Against SARS-CoV-2 in vitro, Evidencing S-Hydroxychloroquine as a Potentially Superior Drug for COVID-19
Creator	Zhao, Jincun Li, Zhe Sun, Jing Li, Xiang Yang, Feng Huang, Yi-You Luo, Hai-Bin Zhang, Xumu Zhang, Tony Li, Guanguan Li, Yingjun Shi, Yongjie
source	BioRxiv
abstract	In all of the clinical trials for COVID-19 conducted thus far and among those ongoing involving chloroquine or hydroxychloroquine, the drug substance used has invariably been chloroquine (CQ) diphosphate or hydroxychloroquine (HCQ) sulfate, i.e., the phosphoric or sulfuric acid salt of a racemic mixture of R- and S-enantiomer (50/50), respectively. As a result, the clinical outcome from previous CQ or HCQ trials were, in fact, the collective manifestation of both R and S- enantiomers with inherent different pharmacodynamic and pharmacokinetic properties, and toxicity liabilities. Our data for the first time demonstrated the stereoselective difference of CQ and HCQ against live SARS-CoV-2 virus in a Biosafety Level 3 laboratory. S-chloroquine (S-CQ) and S-hydroxychloroquine (S-HCQ) significantly more active against SARS-CoV-2, as compared to R-CQ and R-HCQ, respectively. In addition, Mpro, as one of the critical enzymes for viral transcription and replication, also exhibited an enantioselective binding affinity toward the S-enantiomers. The most significant finding from this study is the pronounced difference of the two enantiomers of CQ and HCQ observed in hERG inhibition assay. The IC50 value of S-HCQ was higher than 20 μM against hERG channel, which was much less active over all tested CQ and HCQ compounds. Moreover, S-HCQ alone did not prolong QT interval in guinea pigs after 3 days and 6 days of administration, indicating a much lower cardiac toxicity potential. With these and previous findings on the enantio-differentiated metabolism, we recommend that future clinical studies should employ S-HCQ, substantially free of the R-enantiomer, to potentially improve the therapeutic index for the treatment of COVID-19 over the racemic CQ and HCQ.
has issue date	2020-08-22(xsd:dateTime)
bibo:doi	10.1101/2020.05.26.114033
has license	biorxiv
sha1sum (hex)	834d76302b34efa2a9c3514cf4492c38eeb29791
schema:url	https://doi.org/10.1101/2020.05.26.114033
resource representing a document's title	Enantiomers of Chloroquine and Hydroxychloroquine Exhibit Different Activities Against SARS-CoV-2 in vitro, Evidencing S-Hydroxychloroquine as a Potentially Superior Drug for COVID-19
schema:publication	bioRxiv
resource representing a document's body	covid:834d76302b34efa2a9c3514cf4492c38eeb29791#body_text
is schema:about of	named entity 'Our' named entity 'SARS-CoV-2' named entity 'observed' named entity 'diphosphate' named entity 'COVID-19' named entity 'Hydroxychloroquine' named entity 'Superior' named entity 'EMPLOY' named entity 'USED' named entity 'GUINEA PIGS' named entity 'RACEMIC MIXTURE' named entity 'INVOLVING' named entity 'METABOLISM' named entity 'LABORATORY' named entity 'VIRAL TRANSCRIPTION' named entity 'MUCH' named entity 'employ' named entity 'study' named entity 'SARS-CoV-2' named entity 'active' named entity 'clinical trials' named entity 'pharmacodynamic' named entity 'binding affinity' named entity 'critical' named entity 'global pandemic' named entity 'HCQ' named entity 'plaque assay' named entity 'cell culture' named entity 'mmol' named entity 'SARS-CoV-2 virus' named entity '37 °C' named entity 'HCQ' named entity 'cytokine storm' named entity 'NaOH' named entity 'racemic mixture' named entity 'HCQ' named entity 'autoimmune' named entity 'phosphoric acid' named entity 'Coronavirus' named entity 'rheumatoid arthritis' named entity 'IC50' named entity 'Antiviral' named entity 'HCQ' named entity 'racemates' named entity 'enantiomer' named entity 'HEPES' named entity 'polyclonal antibody' named entity 'HCQ' named entity 'guinea pig' named entity 'pharmacological' named entity 'enantiomers' named entity 'diethylamine' named entity 'United States' named entity 'renal clearance' named entity 'bovine serum albumin' named entity 'hERG' named entity 'malaria' named entity 'combination drug' named entity 'HCQ' named entity 'birth defects' named entity 'racemic' named entity 'racemic' named entity 'half-life' named entity 'International Conference on Harmonization' named entity 'guinea pigs' named entity 'teratogenic' named entity 'racemates' named entity 'half-life' named entity 'guinea pig' named entity 'Kv11.1' named entity 'diphosphate' named entity 'diphosphate' named entity 'antiviral'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software